J Periodontal Res:高胆固醇饮食的牙周炎大鼠的牙周状态,血管反应性和血小板聚集变化

2020-06-29 网络 网络

研究证实,牙周炎与动脉粥样硬化的发展发展相关,并且提出两种疾病的病理发展可能存在双向作用。本研究的目的是研究饮食致高胆固醇血症和结扎引起的Wistar大鼠的结扎性牙周炎之间的相互作用。

研究证实,牙周炎与动脉粥样硬化的发展发展相关,并且提出两种疾病的病理发展可能存在双向作用。本研究的目的是研究饮食致高胆固醇血症和结扎引起的Wistar大鼠的结扎性牙周炎之间的相互作用。

将动物随机分为四个组:C(对照:无牙周炎的标准饮食),Perio(牙周炎+标准饮食),HC(无牙周炎+高胆固醇饮食)和HC + Perio(牙周炎+高胆固醇饮食)。提供饮食45天,第34天结扎Perio和HC-Perio组动物的下颌第一磨牙,保持11天至安乐死。获取下颌骨,并通过宏观和显微断层扫描(µ-CT)成像确定牙槽骨吸收。取血,通过二磷酸腺苷(ADP)和胶原蛋白诱导富含血小板的血浆中的血小板聚集。检测主动脉样本中内皮依赖性血管反应性和内皮(eNOS),磷酸化内皮(peNOS)和诱导型(iNOS)一氧化氮合酶的蛋白表达。

结果发现,与其他组相比,HC饮食+牙周炎(HC + Perio组)与牙槽骨吸收增加有关。在HC + Perio组中,ADP或胶原蛋白诱导的血小板聚集均增加,而乙酰胆碱引起的主动脉舒张性降低最多。单独牙周炎或HC饮食会降低peNOS的表达,而HC饮食会增加iNOS的表达。相反,当两个条件(HC + Perio组)相关时,在血管反应性或血小板聚集中未发现累加或协同作用。

因此,高胆固醇血症可加速由牙周炎引起的骨吸收,而高胆固醇饮食或牙周炎可单独增加大鼠的血小板聚集和血管反应性,而无累加或协同作用。

原文出处:

Natália L. C. Silva,Periodontal status, vascular reactivity, and platelet aggregation changes in rats submitted to hypercholesterolemic diet and periodontitis. Journal of periodontal research, 2020 June. Doi: 10.1111/jre.12730

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728581, encodeId=5bd81e28581b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Sep 11 16:56:13 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022843, encodeId=10ac202284303, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Wed Nov 11 06:56:13 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1451308, encodeId=ef65145130874, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jul 01 14:56:13 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600743, encodeId=447f1600e4373, content=<a href='/topic/show?id=6ea2890503c' target=_blank style='color:#2F92EE;'>#血小板聚集#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89050, encryptionId=6ea2890503c, topicName=血小板聚集)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590618798479, createdName=syscxl, createdTime=Wed Jul 01 14:56:13 CST 2020, time=2020-07-01, status=1, ipAttribution=)]
    2020-09-11 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1728581, encodeId=5bd81e28581b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Sep 11 16:56:13 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022843, encodeId=10ac202284303, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Wed Nov 11 06:56:13 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1451308, encodeId=ef65145130874, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jul 01 14:56:13 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600743, encodeId=447f1600e4373, content=<a href='/topic/show?id=6ea2890503c' target=_blank style='color:#2F92EE;'>#血小板聚集#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89050, encryptionId=6ea2890503c, topicName=血小板聚集)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590618798479, createdName=syscxl, createdTime=Wed Jul 01 14:56:13 CST 2020, time=2020-07-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1728581, encodeId=5bd81e28581b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Sep 11 16:56:13 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022843, encodeId=10ac202284303, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Wed Nov 11 06:56:13 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1451308, encodeId=ef65145130874, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jul 01 14:56:13 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600743, encodeId=447f1600e4373, content=<a href='/topic/show?id=6ea2890503c' target=_blank style='color:#2F92EE;'>#血小板聚集#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89050, encryptionId=6ea2890503c, topicName=血小板聚集)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590618798479, createdName=syscxl, createdTime=Wed Jul 01 14:56:13 CST 2020, time=2020-07-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1728581, encodeId=5bd81e28581b7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Sep 11 16:56:13 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022843, encodeId=10ac202284303, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Wed Nov 11 06:56:13 CST 2020, time=2020-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1451308, encodeId=ef65145130874, content=<a href='/topic/show?id=f0476e49582' target=_blank style='color:#2F92EE;'>#牙周#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67495, encryptionId=f0476e49582, topicName=牙周)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Wed Jul 01 14:56:13 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600743, encodeId=447f1600e4373, content=<a href='/topic/show?id=6ea2890503c' target=_blank style='color:#2F92EE;'>#血小板聚集#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89050, encryptionId=6ea2890503c, topicName=血小板聚集)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=590618798479, createdName=syscxl, createdTime=Wed Jul 01 14:56:13 CST 2020, time=2020-07-01, status=1, ipAttribution=)]

相关资讯

Lancet:P2Y12抑制剂 vs 阿司匹林用于脉粥样硬化患者二级预防

研究认为,与阿司匹林单药治疗相比, P2Y 12抑制剂单一疗法可降低动脉粥样硬化患者心肌梗死风险,但对全因和血管死亡率没有任何影响,P2Y 12抑制剂单一疗法的临床益处值得商榷

Arthritis Rheumatol:多中心SLE队列的动脉粥样硬化性血管事件

这项研究中的AVE患病率和AVE发生率远低于以前发表的数据。

Hypertension:压力感受器所在动脉的粥样硬化程度独立预测缺血性卒中患者的血压下降

BRA较高的总动脉粥样硬化负担与IS患者收缩压和舒张压的下降更平缓独立相关。BRA的总动脉粥样硬化负担对于预测和治疗IS患者的BP下降可能很重要。

全球每300人中有一人!这种病若不治疗,得心脏病或死亡风险是常人20倍

近日,Circulation杂志发表研究显示,全球家族性高胆固醇血症的总患病率为1:311,是全科医生中最常见的遗传性疾病之一,在动脉粥样硬化性心血管疾病(ASCVD)患者中更为常见。

JACC:evolocumab对动脉粥样硬化患者认知功能的影响

FOURIER临床试验结果显示添加到他汀类药物中的evolocumab不会影响患者的认知功能。本研究通过自我调查描述了整个FOURIER试验中患者报告的认知。

Nat Biotech:定向改造肠道微生物群,可抑制动脉粥样硬化的发生

肠道微生物组是具有延展性的微生物群落,对人类和动物的生理健康有着基本影响。肠道微生物组的调节可以促进慢性疾病的发作和发展,例如动脉粥样硬化,心血管疾病,肥胖症,糖尿病和中枢神经系统疾病。而包括饮食在内